SCHEMBL1735496

SCHEMBL1735496

CCN(CC)c1nc(C(N)=O)cc(-c2ccc(OC)nc2)n1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.65
MKNK1 Q9BUB5 1/20 0.49
MKNK2 Q9HBH9 1/20 0.49
GRM2 Q14416 2/20 0.44
NNMT P40261 3/20 0.44
ALDH1A1 P00352 2/20 0.43
HPGD P15428 2/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
TSHR P16473 1/20 0.43
MAPK1 P28482 1/20 0.43
CASP1 P29466 1/20 0.43
CASP7 P55210 1/20 0.43
HSD17B10 Q99714 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
SIRT6 Q8N6T7 1/20 0.42
SCN9A Q15858 1/20 0.41
KLK3 P07288 1/20 0.40
OXTR P30559 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1734177 0.84 KDM4E (0.73) KDM4EGRM2ALDH1A1HPGDLMNA
SCHEMBL1733602 0.83 KDM4E (0.67) KDM4EGRM2ALDH1A1HPGDLMNA
SCHEMBL1734269 0.81 KDM4E (0.71) KDM4EALDH1A1HPGDLMNAMAPT
SCHEMBL1735810 0.80 KDM4E (0.78) KDM4EGRM2ALDH1A1HPGDLMNA
SCHEMBL1735539 0.80 KDM4E (0.70) KDM4EALDH1A1HPGDLMNAMAPT
SCHEMBL1734337 0.79 KDM4E (0.76) KDM4EGRM2ALDH1A1HPGDSCN9A
SCHEMBL1734448 0.79 KDM4E (0.76) KDM4EALDH1A1HPGDLMNAMAPT
SCHEMBL1733735 0.79 KDM4E (0.76) KDM4EGRM2ALDH1A1HPGDLMNA
SCHEMBL1734461 0.79 KDM4E (0.72) KDM4EALDH1A1HPGDLMNAMAPT
SCHEMBL1733607 0.79 KDM4E (1.00) KDM4EALDH1A1HPGDLMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822451-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-09-02 US claimed
EP-1891018-B1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMA (US) 2011-11-16 EP claimed
WO-2011131686-A1 A THERMALLY CONTROLLED ASSEMBLY NAPATECH A/S (DK) 2011-10-27 WO claimed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 US claimed
US-8822451-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-09-02 US disclosed
US-8822451-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-09-02 US disclosed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 US disclosed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105833-A1 Modulators of ATP-binding cassette transporters ABCC4, CFTR, ABCC2 KDM4E 3910/4885MKNK1 3843/4885MKNK2 4261/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.